The knowledge gained from the characterization of genomes, especially the human genome, holds considerable potential for the development of new health care innovations for prevention, diagnosis, and management of many diseases in the coming decade. However, owing to the presence of highly complex scientific, economic, social, and ethical issues associated with this field, societies will need to be better prepared for the era of postgenomics and its consequences. It is important to ensure that the benefits of genomics are distributed fairly among all the countries of the world and that the well-tried and more conventional approaches to medical research and practice are not neglected while the medical potential of genomics is being explored. In this report, the author focuses mainly on human genomics, its applications, development of related technologies and issues related to the dissemination of knowledge derived from genome information, and finally, their impact on global health care.
Lander ES, Linton LM, Birren B., et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.
2.
Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304-1349.
3.
Collins FS, Green ED, Guttmacher AE, Guyer MSA vision for the future of genomic research. Nature. 2003;422:835-847.
4.
Khoury MJ, McCabe LL, McCabe ERPopulation screening in the age of genomic medicine. N Engl J Med. 2003;348:50-58.
5.
Weinshilboum R.Inheritance and drug response. N Engl J Med. 2003;348:529-537.
6.
Roses ADPharmacogenetics and practice of medicine. Nature. 2000;405:857-865.
7.
Hoffman SL, Subramanian GM, Collins FH, Venter JCPlasmodium, human and Anopheles genomics and malaria. Nature . 2002;415:702-709.
8.
Jomaa H., Wiesner J., Sanderbrand S., et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science. 1999;285:1573-1576.
9.
Weintraub LA , Sarwal MMMicroarrays: a monitoring tool for transplant patients? Eur Soc Organ Transplant. 2006;19:775-788.
10.
Livingston DM, Shivdasani R.Towards mechanism-based cancer care. JAMA. 2001;285:588-593.
11.
Schultze JL , Vonderheide RHFrom cancer genomics to cancer immunotherapy: toward second generation tumor antigens. Trends Immunol. 2001;22:516-523.
12.
Levine AE, Steffen DLorCGDB: a database of genes involved in oral cancer. Nucleic Acids Res. 2001;29:300-302.
13.
Zhu S., Okuno Y., Tsujimoto G., Mamitsuka H.Predicting implicit associated cancer genes from OMIM and MEDLINE by a new probabilistic model. BMC Syst Biol. 2007;1:15-16.
14.
Druker BJ, Lydon NBLessons learned from the development of ab1 tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
15.
Schindler T. , Bornmann W., Pellicena P., Miller WT, Clarkson B., Kuriyan J.Structural mechanisms for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938-1942.
16.
Lesage S., Zouali H., Colombel JF, et al. Genetic analyses of chromosome 12 loci in Crohn's disease. Gut. 2000;47:787-791.
17.
Hugot JP, Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
18.
Baier LJ, Permana PA, Yang X., et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest. 2000;106:R69-R73.
19.
Horikawa Y. , Oda N., Cox NJ, et al. Genetic variation in the gene coding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000;26:163-175.
20.
Sachidanandam R., Weissman D., Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928-933.
21.
Neamati N., Joseph JB Jr.New paradigms in drug design and discovery. Curr Topics Med Chem. 2002;2:211-227.
22.
Singh S., Malik BK, Sharma DKMolecular drug targets and structure based drug design: a holistic approach . Bioinformation. 2006;1:314-320.
23.
Wlodawer A., Vondrasek J.Inhibitors of HIV-1 protease: a major success of structure-assisted drug design . Annu Rev Biophys Biomol Struct. 1998;27:249-284.
24.
Greer J., Erickson JW, Baldwin JJ, Varney MDApplication of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem. 1994;37:1035-1054.
25.
Kawakami Y., Inoue A., Kawai T., Wakita M., Sugimoto H., Hopfinger AJThe rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem. 1996;4:1429-1446.
26.
Burke W., Atkins D., Gwinn M., et al. Genetic test evaluation: information needs for clinicians, policy makers, and the public. Am J Epidemiol. 2002 ;156:311-318.
27.
Kaye CI, Laxova R., Livingston JE, et al. Integrating genetic services into public health-guidance for state and territorial programs from the National Newborn Screening and Genetics Resource center (NNSGRC). Com Genet. 2001;4:175-196.
28.
Centers for Disease Control and Prevention. Office of Genomics and Disease Prevention.Genomics workforce competencies 2001. http://www.cdc.gov/genomics/training/competencies/comps.htm. Updated August 14, 2004. Accessed March 12, 2008.
